Shanghai Securities News China Securities Network News - On April 16, the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration showed that Qilu Pharmaceutical's assisted reproductive drug, Cetrorelix Acetate for Injection (Baoyunsheng®), has been approved for marketing and is deemed to have passed the consistency evaluation. So far, Qilu Pharmaceutical has a total of 158 products that have passed the consistency evaluation, 54 of which are the first in China.
Specifically, the approved indication for Qilu Pharmaceutical's Baoyunsheng® is: In assisted reproductive technology, for patients undergoing controlled ovarian stimulation, this product can prevent premature ovulation. This product has been submitted for approval in both China and the U.S., and is expected to receive FDA approval soon.
Qilu Pharmaceutical stated that in recent years, the company has continuously increased its investment in the development of new drug forms such as peptide drugs, committing to researching and developing high-quality, safe, and effective new drug forms that meet more clinical needs, truly ensuring that "the medicine bottles of the Chinese people are firmly held in their own hands." In the future, Qilu Pharmaceutical will continue to uphold the core values of "Great Medical Integrity, Family and Country Under Heaven," focus on unmet clinical medication needs, constantly innovate and break through to bring new hope to patients, and continuously contribute Qilu's strength to the construction of Healthy China. (He Xinyi)